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Delineating the GRIN1 phenotypic
spectrum
A distinct genetic NMDA receptor encephalopathy
ABSTRACT
Objective: To determine the phenotypic spectrum caused by mutations in GRIN1 encoding the
NMDA receptor subunit GluN1 and to investigate their underlying functional pathophysiology.
Methods: We collected molecular and clinical data from several diagnostic and research cohorts.
Functional consequences of GRIN1 mutations were investigated in Xenopus laevis oocytes.
Results: We identified heterozygous de novo GRIN1 mutations in 14 individuals and reviewed the
phenotypes of all 9 previously reported patients. These 23 individuals presented with a distinct
phenotype of profound developmental delay, severe intellectual disability with absent speech,
muscular hypotonia, hyperkinetic movement disorder, oculogyric crises, cortical blindness, gen-
eralized cerebral atrophy, and epilepsy. Mutations cluster within transmembrane segments and
result in loss of channel function of varying severity with a dominant-negative effect. In addition,
we describe 2 homozygous GRIN1 mutations (1 missense, 1 truncation), each segregating with
severe neurodevelopmental phenotypes in consanguineous families.
Conclusions: De novo GRIN1 mutations are associated with severe intellectual disability with cor-
tical visual impairment as well as oculomotor and movement disorders being discriminating pheno-
typic features. Loss of NMDA receptor function appears to be the underlying disease mechanism.
The identification of both heterozygous and homozygous mutations blurs the borders of dominant
and recessive inheritance of GRIN1-associated disorders. Neurology® 2016;86:2171–2178
GLOSSARY
ASD 5 autism spectrum disorder; ID 5 intellectual disability; NMDAR 5 NMDA receptor; SNV 5 single nucleotide variant;
VPA 5 valproate.
NMDA receptors (NMDARs) are tetrameric ligand-gated ion channels permeable to Na1, K1,
and Ca21, composed of 2 glycine binding GluN1 subunits and 2 glutamate binding GluN2/3
subunits (GluN2A, GluN2B, GluN2C, GluN2D, GluN3A, GluN3B).1–3
In contrast to GluN2/3 subunits, which each have specific spatial and temporal expression patterns
throughout the CNS, GluN1 encoded by GRIN1 is a ubiquitous component of the receptor.4,5
Mutations of the NMDAR subunits are associated with a variety of different neurodevelop-
mental phenotypes,3 including intellectual disability (ID),6–8 epilepsy,9–13 and autism spectrum
disorders (ASD), and different psychiatric diseases.14,15
While several studies have focused on the phenotypic spectrum of GRIN2A- and GRIN2B-
associated disorders, little is known about the clinical presentations of individuals with GRIN1
mutations. We reviewed clinical data on individuals with GRIN1 mutations from different
research cohorts as well as from diagnostic laboratories.
In addition, we reviewed available clinical and genetic information from previously re-
ported patients with GRIN1mutations. Nine heterozygous de novo mutations had previously
been reported with rudimentary phenotypic information: 4 individuals were described with
nonsyndromic and nonspecific ID (mental retardation, autosomal dominant 8, OMIM
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614254),8,16,17 1 individual had epileptic
encephalopathy of Lennox-Gastaut type,9
and 4 individuals were described with severe
developmental delay and associated move-
ment disorders.18
Our study aimed at a comprehensive delin-
eation of the associated phenotype and at an
investigation of the functional consequences
of the identified GRIN1 mutations.
METHODS Patients. We reviewed clinical and genetic infor-
mation on patients in whom GRIN1 mutations were detected
through different next-generation sequencing approaches in
diagnostic and research settings including targeted panel
sequencing19 or whole-exome sequencing (table e-1, a and b, on
the Neurology® Web site at Neurology.org). Depending on the
availability of parental samples, the de novo status of each
mutation was confirmed through conventional Sanger sequencing.
Standard protocol approvals, registration, and patient
consents. Written informed consent for genetic testing was ob-
tained for every individual. Genetic testing within research set-
tings was approved by the Commission of Medical Ethics of
the University of Antwerp, Belgium; the Ethics Committee of
Western Zealand, Denmark; the Kantonale Ethikkommission
Zürich, Switzerland; and additional local ethics committees of
the contributing centers.
In silico prediction. Predictions of the functional impact of
identified coding variants were assessed by different in silico anal-
ysis programs (PolyPhen2, http://genetics.bwh.harvard.edu/
pph2/ and MutationTaster, http://www.mutationtaster.org)
using the GRIN1 transcript number ENST00000371561
(table e-2). Variants were compared to 60,706 controls of the
ExAC browser (http://exac.broadinstitute.org/). Conservation of
mutated positions was evaluated using sequence alignment of
different species (figure e-1). Molecular modeling of the
NMDAR subunits was performed according to Endele et al.7
DNA constructs, oocyte expression, and electrophysiology.
For Xenopus laevis oocyte experiments, GluN1 and GluN2B con-
structs and capped cRNAs were generated as described previ-
ously.11,12 Several mutations were introduced into these constructs
using the QuikChange site-directed mutagenesis kit (Stratagene;
Agilent Technologies, Santa Clara, CA) and confirmed by DNA
sequencing. Oocytes were isolated and maintained as described
previously.20 Glutamate, glycine, and Zn21 dose–response curves
of wild-type GluN1/GluN2B and mutant NMDARs were
analyzed by 2-electrode voltage clamp recording as described.21
Concentration–response curves and current traces shown in the
figures were drawn using KaleidaGraph (Synergy Software,
Reading, PA). Data represent means 6 SE. Statistical significance
was evaluated using a Student 2-tailed unpaired t test if not
otherwise stated. All chemicals used were obtained from Sigma.
RESULTS We identified 14 previously unreported
patients with heterozygous GRIN1 mutations. In 13
individuals, the mutation was confirmed to be de
novo, whereas in patient 22 parental samples were
not available for segregation analysis. However, given
that the particular mutation in patient 22 was recur-
rent in 2 other patients (patients 21 and 23) and
absent in large control datasets, we concluded that
the mutation is pathogenic and included this patient
in our analysis. In addition to these 14 novel cases, we
reviewed phenotypic data of all 9 previously reported
cases8,9,16–18 and present additional clinical informa-
tion on 4 of these patients.8,9,16 Thus, we were able to
collectively review the clinical data of 23 patients
(table 1). In addition to patients with de novo GRIN1
mutations, we identified 2 homozygous GRIN1 mu-
tations segregating in 2 unrelated families with severe
neurodevelopmental disorders (1.1–2 and 5.1–3). In
both cases, family members carrying heterozygous
GRIN1 variants were unaffected.
Phenotypes associated with heterozygous de novo GRIN1
mutations. Almost all patients carrying a de novo
GRIN1 mutation presented with profound global
developmental delay, usually already apparent in the
neonatal period and resulting in severe intellectual
disability (21/22; 95%). (table e-1, a and b) Patients
usually never acquired the ability to walk and had
absent or extremely limited verbal communication
skills.
Of the 21 patients in whom information regarding
muscular tone could be retrieved, 15 (71%) had
severe truncal and initial appendicular hypotonia.
Many patients developed corticospinal signs, such as
hyperreflexia (6/21; 29%) or spasticity (6/21; 29%),
consistent with a diagnosis of spastic quadriparesis.
The majority of patients showed choreatic, dystonic,
or dyskinetic movement disorders (14/23; 61%),
including oculomotor abnormalities such as oculogy-
ric crises (5/23; 22%). Nonspecific stereotypic move-
ments were noted in 7/21 patients (33%).
A significant proportion of patients (16/23; 70%)
had epilepsy. The epilepsy phenotype of GRIN1muta-
tion carriers was variable with respect to age at onset
(day of life 1–11 years), seizure semiology (infantile
spasms, tonic and atonic seizures, hypermotor seizures,
focal dyscognitive seizures, febrile seizures, generalized
seizures, status epilepticus), and the associated EEG
pattern (hypsarrhythmia, focal, multifocal and general-
ized spikes and waves). In addition to the variability of
the epilepsy phenotype, the outcome relating to the
control of seizures was variable: while at least 5 patients
(5/16; 31%) had therapy-resistant epilepsy, 2 patients
became seizure-free or had long periods of seizure free-
dom on valproate (VPA), whereas 2 additional patients
responded well on a combination of topiramate, leve-
tiracetam, and clobazam or the introduction of vigaba-
trin and clonazepam in addition to VPA. In most other
epilepsy patients, clinical data were not available or
seizures were not reported as a prominent phenotype
(table e-3, a and b). Given this variability, the epilepsy
phenotype of GRIN1mutation carriers usually did not
resemble specific forms of epileptic encephalopathies,
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which is in contrast to GRIN2A- and some GRIN2B-
associated disorders.9–13
At least 8 GRIN1 patients were diagnosed with
ASD or ASD-like features (8/23; 35%), acknowledg-
ing that the severe level of ID in most patients made
a separate diagnosis of ASD challenging. This is in
line with previous reports in GRIN2B-associated dis-
orders14: 4 individuals presented with aggression and
self-injurious behavior or disturbed pain perception
(4/23; 17%). Eight patients (8/23; 35%) had
nonspecified sleep disorders. Several patients had
feeding difficulties (9/23; 39%), likely due to their
underlying hypotonia and spasticity, requiring tube
feeding in some patients. Several patients presented
with cortical visual impairment or delayed visual mat-
uration (5/23; 22%).
MRI findings were available for review in 19 pa-
tients, and nonspecific volume loss or atrophy was
Table 1 Phenotypes of cases with GRIN1 mutations
ID
Mutation
(NM_007327)
Mutation
(protein) Zygosity Origin
Protein
domain Functional effect Consequence Phenotype
1.1 c.649C.T p.Arg217Trp Hom Biparental NTD Increased Zn21 inhibition LoF (mild) Severe ID, MD
1.2 c.649C.T p.Arg217Trp Hom Biparental NTD Increased Zn21 inhibition LoF (mild) Severe ID, MD
2 c.1654A.C p.Ser549Arg Het De novo Pre-M1 Severe ID, MD, Sz
3 c.1656C.A p.Asp552Glu Het De novo Pre-M1 Severe ID, MD, Sz,
CVI
4a c.1656C.A p.Asp552Glu Het De novo Pre-M1 Severe ID, Sz
5.1 c.1666C.T p.Gln556* Hom Biparental Pre-M1 Nonfunctional LoF (complete) Fatal EE
5.2 c.1666C.T p.Gln556* Hom Biparental Pre-M1 Nonfunctional LoF (complete) Fatal EE
5.3 c.1666C.T p.Gln556* Hom Biparental Pre-M1 Nonfunctional LoF (complete) Fatal EE
6a c.1670C.G p.Pro557Arg Het De novo Pre-M1 Reduced maximal agonist-inducible
currents
LoF (complete) Severe ID
7a c.1679_1681dupGCA p.Ser560dup Het De novo Pre-M1 Reduced activity of receptor LoF (complete) Severe ID, Sz, CVI
8 c.1852 G.C p.Gly618Arg Het De novo M2 Nonfunctional LoF (complete) Severe ID
9 c.1858G.C p.Gly620Arg Het De novo M2 Nonfunctional LoF (complete) Severe ID
10a c.1923G.A p.Met641Ile Het De novo M3 Severe ID, MD, Sz
11 c.1933G.T p.Ala645Ser Het De novo M3 Similar to wild-type Unclear Severe ID, Sz, CVI
12a c.1940A.C p.Tyr647Ser Het De novo M3 Reduced maximal agonist-inducible
currents
LoF
(intermediate)
Severe ID, Sz
13a c.1950C.G p.Asn650Lys Het De novo M3 Severe ID, MD, Sz
14a c.1984G.A p.Glu662Lys Het De novo S2 Mild ID
15a c.2443G.A p.Gly815Arg Het De novo M4 Reduced maximal agonist-inducible
currents
LoF (complete) Severe ID, MD, Sz
16 c.2443G.A p.Gly815Arg Het De novo M4 Reduced maximal agonist-inducible
currents
LoF (complete) Severe ID, MD, Sz,
CVI
17 c.2443G.A p.Gly815Arg Het De novo M4 Reduced maximal agonist-inducible
currents
LoF (complete) Severe ID, MD, Sz,
CVI
18 c.2444G.T p.Gly815Val Het De novo M4 Severe ID, MD, Sz
19 c.2449T.C p.Phe817Leu Het De novo M4 Reduced maximal agonist-inducible
currents
LoF
(intermediate)
Severe ID
20a c.2449T.C p.Phe817Leu Het De novo M4 Reduced maximal agonist-inducible
currents
LoF
(intermediate)
ID, MD
21 c.2479G.A p.Gly827Arg Het De novo M4 Nonfunctional LoF (complete) Severe ID, MD
22 c.2479G.A p.Gly827Arg Het Unknown M4 Nonfunctional LoF (complete) Severe ID, MD, Sz
23 c.2479G.A p.Gly827Arg Het De novo M4 Nonfunctional LoF (complete) Severe ID, MD, Sz
24 c.2530C.T p.Arg844Cys Het De novo CBD Similar to wild-type Unclear Severe ID, MD, Sz
25 c.2530C.T p.Arg844Cys Het De novo CBD Similar to wild-type Unclear Severe ID, MD, Sz
Abbreviations: CBD 5 Ca21-calmodulin binding domain; CVI 5 cortical visual impairment; Het 5 heterozygous; Hom 5 homozygous; ID 5 intellectual
disability; LoF 5 loss of function; M1-4 5 transmembrane domains; MD 5 movement disorder; NTD 5 aminoterminal domain; S1-2 5 ligand binding
domains; Sz 5 seizures.
Summary of phenotypic information of all published (a) and novel cases with GRIN1mutations. The data comprise 23 patients with heterozygous proven (or
likely) de novo mutations as well as 2 families (families 1 and 5) with homozygous GRIN1 mutations.
Neurology 86 June 7, 2016 2173
seen in 11/19 (58%) patients. These MRI findings
were considered insufficient to explain the presence
of quadriplegia or movement disorder seen in pa-
tients. Cortical atrophy was apparent already at young
ages (e.g., cases 18 at 20 months and 25 at 3 years of
age) without evidence for a significant age-dependent
progression.
Two patients (2/21; 10%) had a marfanoid habi-
tus, whereas several had normal stature or growth
retardation or low body weight. Microcephaly was
observed in 6/23 (26%) patients. Dysmorphic fea-
tures, if present, were subtle. Deep-set eyes, which
were previously reported as a common feature,18
could not be consistently seen in our patients.
While 21/22 patients had severe ID, one previously
reported patient carrying aGRIN1 p.Glu662Lys muta-
tion presented with a less severe phenotype.8 Patient 14
was able to walk independently at age 18 months and
had speech delay with adequate first words at 9 months
and 2-word phrases only at 5 years of age. Additionally,
the patient did not present with any other comorbid
conditions including epilepsy, movement disorder, and
abnormalities of muscle tone or vision.
GRIN1mutations with recessive inheritance. In a consan-
guineous family with ID and ASD, a homozygous
GRIN1 p.Arg217Trp missense variant was found in
2 affected brothers. Both parents were healthy hetero-
zygous carriers. The variant was predicted to be path-
ogenic (table e-2) and was absent in ExAC controls.
In a second consanguineous family, we identified
a homozygous p.Gln556* truncation mutation in 3
siblings with severe neonatal epileptic encephalopa-
thy. All 3 siblings died between 5 days of life and 5
months secondary to intractable seizures. Both pa-
rents were unaffected heterozygous carriers of the
p.Gln556* mutation.
Among the 110 ExAC-annotated missense and 8
truncating GRIN1 variants, none was reported to be
homozygous in 60,706 control samples.
Spectrum and clustering of GRIN1 mutations. All 16 dif-
ferent de novo mutations identified in the 23 novel and
published cases are missense alterations and cluster
within or in close proximity to the transmembrane do-
mains forming the intrinsic ion channel pore of the
receptor (figure 1). Interestingly, this region is widely
spared fromgenetic variation in controls and shows a high
level of conservation in different species (figure e-1). In
contrast, there is extensive enrichment of reported single
nucleotide variants (SNV) in controls in the N-terminal
domain as well as the C-terminus of GRIN1. De novo
mutations have not been observed in either domain. The
reported mutations do not allow us to assess the genetic
variability of S1 and S2 ligand binding sites. However,
the S1 domain contains numerous and frequent SNV
but no disease-causing mutations so far, whereas S2
showed less variability with only 2 nonrecurrent SNV
but one mutation (figure 1). Moreover, this single
mutation detected within S2 was associated with the
mildest phenotype (patient 14) when compared to all
other GRIN1 de novo mutations closely related to the
transmembrane domains. Five de novo mutations have
been detected recurrently in independent patients within
our cohort (p.Asp552Glu, p.Gly815Arg, p.Phe817Leu,
p.Gly827Arg, p.Arg844Cys).
The only mutation being far outside the trans-
membrane cluster is the p.Arg217Trp missense vari-
ant that was identified in a recessive family with
unaffected heterozygous carriers.
Functional investigations. Ectopic expression of the
GluN1 mutants with wild-type GluN2B subunits
revealed that 4 of the mutants gave no response to
up to 10 mM glutamate and glycine and were hence
rated as nonfunctional (p.Gln556*, p.Gly618Arg,
p.Gly620Arg, p.Gly827Arg; n 5 10, each). For
all other mutants, changes in maximal inducible
currents and agonist affinities were examined. Four
mutations (p.Pro557Arg, p.Tyr647Ser, p.Gly815Arg,
p.Phe817Leu) resulted in a highly significant reduction
Figure 1 Domains of GRIN1 and distribution of variants
Signal peptide (SP), the extracellular N-terminal domain, and ligand binding sites (S1, S2), the transmembrane domains (M1-4), as well as the intracellular
C-terminal domain (CTD) with the proximal Ca21 calmodulin binding domain (CBD). De novo mutations (red) cluster within or in very close proximity to
M1-4. In addition, this region is particularly spared from nonsynonymous genetic variation according to the ExAC browser (rare/single variants, gray;
repeated/frequent variants, black). The 2 homozygous GRIN1 variants are marked in blue.
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of agonist Imax values (p , 0.001, n 5 5–9; figure
e-2a). Our model of the GRIN1/GRIN2B NMDAR11
predicts strong intersubunit and intrasubunit
interactions between adjacent helical structures
M3 and M4 for mutated positions p.Pro557,
p.Tyr647, p.Gly815, p.Phe817, and p.Gly827,
thereby destabilizing the quaternary structure of
the receptor transmembrane domains and
disturbing assembly of NMDARs. Consistent
with an impaired function of GRIN1 de novo
mutations, analysis of the agonist dose-response
curves for mutations p.Gly815Arg and p.Phe817Leu
additionally revealed a highly significant reduction in
the affinities for both glutamate and glycine (figure
e-2b). For positions p.Gly618 and p.Gly620, our
model predicts a location in the membrane re-
entrant loop (the P-loop) of the GluN1 subunit,
which determines the narrow constriction and ion
selectivity of the channel. Thus, conversion of the
pore residues p.Gly618 and p.Gly620 to a charged
arginine side chain likely has strong impact on
NMDA channel properties. Coexpression of wild-type
GluN1 with mutants GluN1 p.Tyr647Ser or
p.Phe817Leu resulted in intermediate effects of agonist
Imax values (p , 0.01, n 5 5), supporting the idea of
a negative impact of the substitutions on the function
of hetero-oligomeric NMDARs (figure e-2c). Mutations
p.Arg217Trp, p.Ala645Ser, and p.Arg844Cys generated
functional receptors with agonist Imax values (p. 0.05,
n5 5) similar to wild-type (data not shown). Functional
analysis of the missense alteration GluN1 p.Arg217Trp
in the N-terminal Zn21-binding domain with wild-type
GluN2A subunits showed a significant increase in Zn21
inhibition (figure e-2d), suggesting impaired activation
in vivo due to increased tonic inhibition of
GRIN1Arg217Trp–GRIN2A receptors at physiologic
concentrations of Zn21. However, functional analysis of
mutations p.Ala645Ser and p.Arg844Cys revealed no
significant effects on agonist Imax values or affinity,
suggesting that these 2 substitutions may alter
NMDAR function through other mechanisms. For
example, since the recurrent substitution p.Arg844Cys
is located in the intracellular Ca21-calmodulin-binding
domain, disturbed interactions with intracellular
proteins may impair receptor function. Our analyses
of de novo mutations are consistent with a dominant-
negative effect resulting in a significant loss of receptor
function.
DISCUSSION We reviewed 14 novel and 9 previ-
ously published individuals carrying heterozygous
GRIN1 de novo mutations associated with neurode-
velopmental phenotypes.
Profound developmental delay associated with
severe ID and lack of speech development are pre-
dominant features, and muscular hypotonia leading
to spastic quadriplegic cerebral palsy, hyperkinetic
movement disorders including dystonia and chorea,
and oculomotor abnormalities as well as cortical
visual impairment appeared to be recurrent findings
in individuals with GRIN1 encephalopathy. While
some of these features can be seen in other genetic
epileptic encephalopathies such as SCN2A and SCN8A
encephalopathies (OMIM 613721, 600702), these
findings are novel in the context of NDMAR en-
cephalopathies. Seizures occurred in about two-
thirds of cases. However, there was no obvious
epilepsy pattern with respect to age at onset,
seizure semiology, EEG features, or outcome. Fur-
thermore, the frequency of epilepsy in GRIN1
patients may be an overestimate due to inclusion
of a high proportion of epilepsy patients in the
screening cohorts.
GRIN1 encodes GluN1 and autoantibodies pri-
marily targeting an epitope within the N-terminal
domain of GluN1 result in the increasingly recog-
nized clinical entity of NMDAR encephalitis.22,23
NMDAR encephalitis is an acute paraneoplastic or
parainfectious neurologic disorder where decay of
NMDARs is considered to be the underlying patho-
mechanism, partially paralleling the pathophysiology
of GluN1 loss of function seen in our patients with
GRIN1 encephalopathy. While the acuity of the clin-
ical presentation is vastly different, with NMDAR
encephalitis presenting as an acute acquired condition
while GRIN1 encephalopathy is a chronic neurode-
velopmental disease, we would like to emphasize
a shared group of symptoms including choreatic
and dystonic movements, seizures, and sleep cycle
dysregulation, which we observe in our patient
cohort. Further research will be able to address the
question whether the GRIN1 encephalopathy pheno-
type is specific enough to hypothesize a spectrum of
NMDAR impairment in human disease.
GRIN1 de novo mutations cluster within or in
direct proximity to the transmembrane domains of
GRIN1 (figure 1). These regions are largely spared
from genetic variation, underlining the crucial impor-
tance of these domains. The sole mutation outside
this cluster is p.Arg217Trp, which appears to be only
pathogenic when present homozygously and thus
might mediate its effect through different effects com-
pared to the heterozygous variants near the trans-
membrane domains.
All reported de novo mutations are missense var-
iants. In contrast to GRIN2A and GRIN2B, hetero-
zygous truncation of GRIN1 apparently does not
result in a neurologic phenotype. Furthermore, both
deletions encompassing GRIN1 as well as truncating
or splice-site variants are seen in control databases,
suggesting that haploinsufficiency in GRIN1, albeit
rare, is tolerated in the human population.
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In addition to 16 different heterozygous de novo
mutations, we describe 2 recessive GRIN1mutations.
The homozygous loss-of-function p.Arg217Trp
mutation segregated with severe ID, ASD, and move-
ment disorders in 2 affected siblings in a consanguin-
eous family (family 1), and a homozygous p.Gln556*
truncation mutation was found in 3 individuals with
fatal epileptic encephalopathy in family 5 (table 1).
As the NMDAR obligatorily contains 2 GluN1
subunits, truncation or lack of both GRIN1 alleles
would result in a knock-out and complete deprivation
of the NMDAR. The almost continuous seizure
activity with suppression-burst EEG and early death
of all 3 affected siblings in family 5 underlines the
vital role of GluN1 in NMDAR functioning.
This disease mechanism as well as functional data
point towards a dominant-negative effect. In contrast
to the gain of function frequently detected in other
GRIN-associated neurodevelopmental disorders,11,12
GRIN1 de novo mutations p.Pro557Arg, p.Ser560d-
up, p.Gly618Arg, p.Gly620Arg, p.Tyr647Ser,
p.Gly815Arg, p.Phe817Leu, and p.Gly827Arg
result in a loss of function.
The extent and nature of the loss of NMDAR
function due to de novo GRIN1 mutations corre-
sponded only marginally to the uniformly severe phe-
notypes. One possible explanation for this lack of
genotype–phenotype correlation may be effects on
the subunit composition or trafficking of the
NMDAR that potentially lead to a shared secondary
mechanism compensating GluN1 defects indepen-
dent of the individual severity of the respective
GRIN1 mutation eventually escaping visualization
using standard artificial in vitro models.
Given the multiple observations of heterozygous
de novo GRIN1 loss-of-function mutations, GRIN1-
associated disorders are a recurrent cause of severe and
complex neurodevelopmental disorders. Additionally,
homozygous GRIN1 mutations segregating with severe
phenotypes display phenotypic overlap with individuals
carrying heterozygous GRIN1 de novo mutations. This
observation blurs the borders of autosomal-dominant
and autosomal-recessive inheritance. The constellation
of severe ID and associated findings including promi-
nent hypotonia, movement disorders, oculogyric crises,
cortical visual impairment or blindness, absent speech,
behavioral issues, sleep disorder, and seizures may allow
for a phenotypic differentiation from other frequent
forms of severe ID. Together with the catastrophic phe-
notype seen in homozygous truncation mutation car-
riers, our findings underscore the essential role of the
NMDAR subunits in neurodevelopment.
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